Connection
Michael Bristow to Stroke Volume
This is a "connection" page, showing publications Michael Bristow has written about Stroke Volume.
|
|
Connection Strength |
|
 |
|
 |
|
4.276 |
|
|
|
-
Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 04; 7(4):281-290.
Score: 0.521
-
Bristow MR. Contractile reserve and the response to cardiac resynchronization therapy. Int J Cardiol. 2018 02 01; 252:234-235.
Score: 0.485
-
Bristow MR, Kao DP, Breathett KK, Altman NL, Gorcsan J, Gill EA, Lowes BD, Gilbert EM, Quaife RA, Mann DL. Structural and Functional Phenotyping of the Failing Heart: Is the Left Ventricular Ejection Fraction Obsolete? JACC Heart Fail. 2017 11; 5(11):772-781.
Score: 0.477
-
Bristow MR, Altman NL. Heart Rate in Preserved Ejection?Fraction?Heart Failure. JACC Heart Fail. 2017 11; 5(11):792-794.
Score: 0.475
-
Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
Score: 0.433
-
Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, DeMets D, Bristow MR. The Addition of a Defibrillator to?Resynchronization Therapy Decreases?Mortality in Patients With Nonischemic Cardiomyopathy. JACC Heart Fail. 2021 06; 9(6):439-449.
Score: 0.152
-
Purmah Y, Lei LY, Dykstra S, Mikami Y, Cornhill A, Satriano A, Flewitt J, Rivest S, Sandonato R, Seib M, Lydell CP, Howarth AG, Heydari B, Merchant N, Bristow M, Fine N, Gaztanaga J, White JA. Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease. Circ Cardiovasc Imaging. 2021 03; 14(3):e011337.
Score: 0.151
-
Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
Score: 0.150
-
Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
Score: 0.120
-
Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm. 2017 06; 14(6):858-865.
Score: 0.114
-
Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017 01 26; 2(2):e89169.
Score: 0.113
-
Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of ?-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr; 8(2):270-83.
Score: 0.099
-
Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
Score: 0.085
-
Bristow MR. Pharmacogenetic targeting of drugs for heart failure. Pharmacol Ther. 2012 Apr; 134(1):107-15.
Score: 0.080
-
Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
Score: 0.073
-
De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb; 14(1):9-18.
Score: 0.061
-
Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007 Nov; 13(9):769-73.
Score: 0.060
-
Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
Score: 0.048
-
Mallabone M, Labib D, Abdelhaleem A, Dykstra S, Thompson RB, Paterson DI, Thompson SK, Hasanzadeh F, Mikami Y, Rivest S, Flewitt J, Feng Y, Macdonald M, King M, Bristow M, Kolman L, Howarth AG, Lydell CP, Miller RJH, Fine NM, White JA. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2024 May 31; 25(6):804-813.
Score: 0.047
-
Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, Bozkurt B, Bristow MR, Butler J, Carson PE, Felker GM, Jessup M, Murillo J, Kondo T, Solomon SD, Abraham WT, O'Connor CM, Psotka MA. Left Ventricular Ejection Fraction and the Future of Heart?Failure Phenotyping. JACC Heart Fail. 2024 Mar; 12(3):451-460.
Score: 0.046
-
Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 06; 24(6):1080-1090.
Score: 0.041
-
Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
Score: 0.041
-
Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
Score: 0.040
-
Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psotka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, Butler J. Treatment of HF in an Era of Multiple?Therapies: Statement From the HF Collaboratory. JACC Heart Fail. 2021 01; 9(1):1-12.
Score: 0.037
-
Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
Score: 0.033
-
Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
Score: 0.030
-
Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
Score: 0.028
-
Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left?Ventricular Morphology, and Heart?Failure?Risk: The MESA Study. J Am Coll Cardiol. 2016 Apr 05; 67(13):1544-1552.
Score: 0.027
-
Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
Score: 0.025
-
Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, G?rg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015; 419-30.
Score: 0.024
-
Gilbert EM, Olsen SL, Renlund DG, Bristow MR. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993 Mar 25; 71(9):23C-29C.
Score: 0.022
-
Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
Score: 0.021
-
Dibble CT, Lima JAC, Bluemke DA, Chirinos JA, Chahal H, Bristow MR, Kronmal RA, Barr RG, Ferrari VA, Propert KJ, Kawut SM. Regional left ventricular systolic function and the right ventricle: the multi-ethnic study of atherosclerosis right ventricle study. Chest. 2011 Aug; 140(2):310-316.
Score: 0.019
-
Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, Kizer JR, Lima JA, Kawut SM. Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):659-67.
Score: 0.018
-
MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
Score: 0.016
-
Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
Score: 0.011
-
McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
Score: 0.011
-
Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 03; 344(18):1358-65.
Score: 0.009
-
Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
Score: 0.009
-
Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
Score: 0.009
-
Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
Score: 0.008
-
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|